Stryker (SYK) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Mar, 2026Executive summary
The annual meeting will be held virtually on May 6, 2026, with shareholders voting on director elections, auditor ratification, and executive compensation approval.
Shareholders of record as of March 9, 2026, are eligible to vote, with multiple voting methods available.
The proxy statement includes forward-looking statements and outlines procedures for submitting proposals for the 2027 meeting.
Voting matters and shareholder proposals
Shareholders will vote to elect ten directors, ratify Ernst & Young LLP as the independent auditor for 2026, and approve executive compensation on an advisory basis.
Shareholders can submit proposals for the 2027 meeting under SEC Rule 14a-8 and nominate directors via proxy access if eligibility criteria are met.
Board of directors and corporate governance
The board consists of ten nominees with diverse backgrounds and skills, with an average tenure of 11 years.
All directors except the Chair/CEO are independent; robust governance practices include annual elections, majority voting, and regular board refreshment.
The board has Audit, Compensation and Human Capital, and Governance and Nominating Committees, all composed of independent directors.
The Lead Independent Director has significant responsibilities, and the board regularly evaluates its leadership structure.
Latest events from Stryker
- Definitive additional proxy materials filed for shareholder voting, with no fee required.SYK
Proxy filing23 Mar 2026 - Strategy targets digital, M&A, and margin gains, with double-digit EPS growth through 2028.SYK
Investor Day 20253 Feb 2026 - Q2 organic sales up 9%, adjusted EPS up 10.6%, and guidance raised on strong demand.SYK
Q2 20242 Feb 2026 - Double-digit growth, record Mako installs, and strong 2026 outlook despite tariff headwinds.SYK
Q4 20252 Feb 2026 - Mako innovation, easing pricing, and new launches drive growth and share gains into 2025.SYK
2024 Wells Fargo Healthcare Conference22 Jan 2026 - Q3 net sales up 11.9% and adjusted EPS up 16.7%, with strong 2024 outlook and M&A momentum.SYK
Q3 202418 Jan 2026 - Double-digit organic growth and margin expansion, with portfolio moves and Spine impairments.SYK
Q4 20249 Jan 2026 - Double-digit sales growth, innovation, and all proposals approved amid leadership transitions.SYK
AGM 20258 Jan 2026 - 2025 targets 8%-9% growth, margin expansion, and innovation through ASC, robotics, and M&A.SYK
Citi’s 2025 Medtech and Life Sciences Access Day7 Jan 2026